SCHEDULE 13G/A: BlackRock Discloses 1.5% Stake in INOVIO PHARMACEUTICALS INC

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 1.5% of INOVIO PHARMACEUTICALS INC's common stock as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 3 to Schedule 13G concerning its beneficial ownership in INOVIO PHARMACEUTICALS INC.
• As of June 30, 2025, BlackRock, Inc. beneficially owns 537,627 shares of INOVIO PHARMACEUTICALS INC common stock.
• This ownership represents 1.5% of the total class of securities.
• BlackRock, Inc. holds sole voting power over 534,917 shares and sole dispositive power over 537,627 shares.
• No shared voting or dispositive power is reported.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc.'s principal executive offices are located at 50 Hudson Yards, New York, NY 10001.
• INOVIO PHARMACEUTICALS INC's principal executive offices are located at 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA 19462.
• Subsidiaries of BlackRock, Inc. involved in the beneficial ownership include BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC; however, no single subsidiary holds 5% or more of the outstanding shares.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of an institutional investor's stake, providing factual information without inherent positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• BlackRock, Inc. holds its stake in INOVIO PHARMACEUTICALS INC in the ordinary course of business, indicating a standard investment rather than an activist position.

Negatives

• The filing indicates that BlackRock, Inc.'s stake is not for the purpose of changing or influencing control of INOVIO PHARMACEUTICALS INC, which means it is a passive investment and does not signal potential strategic changes driven by this investor.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding INOVIO PHARMACEUTICALS INC's future performance or strategic outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing is a routine disclosure of an institutional investor's passive stake in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics for INOVIO PHARMACEUTICALS INC.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, BlackRock, Inc., holds a passive stake in the company, which may provide a degree of stability or confidence, but does not indicate any intent to influence corporate strategy.

Key Dates

Keywords

INOVIO PHARMACEUTICALS INC, BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing